| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
di-Ellipticine-RIBOTAC (compound 7) (5-500 nM) TFA inhibited RAN translation of r(G4C2)66 in HEK293T cells and reduced transcripts containing r(G4C2)exp in a dose-dependent manner [1]. di-Ellipticine-RIBOTAC (5-500 nM) TFA selectively reduced the abundance of C9orf72 intron 1 with an IC50 of approximately 50 nM. di-Ellipticine-RIBOTAC TFA also reduced the abundance of poly(GP) in lymphoblastic cell lines (LCLs) and induced pluripotent stem cells (iPSCs) derived from c9ALS patients [1]. di-Ellipticine-RIBOTAC (50 nM; 2.5 weeks) TFA reduced C9orf72 transcripts containing intron 1 of r(G4C2)exp in iPSC-derived spinal neurons (iPSNs) from c9ALS patients and reversed the loss of Nup98[1]. di-Ellipticine-RIBOTAC TFA cleaved Cy5- and Cy3-labeled r(G4C2)8 RNA in the presence of RNase L[1]. di-Ellipticine-RIBOTAC TFA inhibited the binding of hnRNP H1 to r(G4C2)8 RNA (IC50 = 2.4 μM)[1].
|
|---|---|
| ln Vivo |
di-Ellipticine-RIBOTAC (compound 7) (33 nmol; intraventricular injection; single solution) TFA attenuated c9ALS/FTD pathology in a C9orf72 cytokine cell model (+/+PWR500)[1]. +/+PWR500 (12-25 weeks old) (expressing 500 r(G4C2) repeats)[1] 33 nanomolar ICV; compared with the mediator-treated control, a single dose reduced the abundance of intron 1 mRNA containing r(G4C2)exp by 44%, reduced the number of nuclear foci containing r(G4C2)exp, reduced the abundance of aggregate (GP) in brain tissue by 74%, reduced aggregate (GP) and aggregate (GA) aggregates, and reduced TDP-43 inclusions.
|
| References |
| Molecular Formula |
C80H88F3N7O18S
|
|---|---|
| Molecular Weight |
1524.65
|
| CAS # |
2767983-77-5
|
| Related CAS # |
di-Ellipticine-RIBOTAC; 2767983-76-4
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6559 mL | 3.2794 mL | 6.5589 mL | |
| 5 mM | 0.1312 mL | 0.6559 mL | 1.3118 mL | |
| 10 mM | 0.0656 mL | 0.3279 mL | 0.6559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
